Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial

Shankar Siva, Mathias Bressel, Mark Sidhom, Swetha Sridharan, Ben Vanneste, Ryan Davey, Rebecca Montgomery, Jeremy Ruben, Farshad Foroudi, Braden Higgs, Chin‐Teng Lin, Avi Raman, Nicholas Hardcastle, Michael S. Hofman, Richard De Abreu Lourenço, Mark Shaw, Pascal Mancuso, Daniel Moon, Lih‐Ming Wong, Nathan Lawrentschuk, Simon Wood, Nicholas R. Brook, Tomas Kron, Jarad Martin, David Pryor, Brent Chesson, Muhammad Ali, Sarat Chander, Alisha Moore, Olivia Cook, Thomas Eade, Harish Sharma, Muralidas Ramanathan, Kate Howe, Helen FrewenThe Lancet Oncology 2024 · DOI

BibTeX
@inproceedings{siva2024stereotactic,
  author = {Shankar Siva and Mathias Bressel and Mark Sidhom and Swetha Sridharan and Ben Vanneste and Ryan Davey and Rebecca Montgomery and Jeremy Ruben and Farshad Foroudi and Braden Higgs and Chin‐Teng Lin and Avi Raman and Nicholas Hardcastle and Michael S. Hofman and Richard De Abreu Lourenço and Mark Shaw and Pascal Mancuso and Daniel Moon and Lih‐Ming Wong and Nathan Lawrentschuk and Simon Wood and Nicholas R. Brook and Tomas Kron and Jarad Martin and David Pryor and Brent Chesson and Muhammad Ali and Sarat Chander and Alisha Moore and Olivia Cook and Thomas Eade and Harish Sharma and Muralidas Ramanathan and Kate Howe and Helen Frewen},
  title = {{Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial}},
  booktitle = {The Lancet Oncology},
  year = {2024},
  doi = {10.1016/s1470-2045(24)00020-2},
}

Loading related content...

Figure